Also considered
27 papers judged, 3 emailed · Read the digest →
Phase 3 RCT in high-risk early-stage inoperable NSCLC treated with SBRT with or without perioperative atezolizumab, published in Lancet. Tests whether adding immunotherapy to definitive SBRT improves overall survival, potentially changing management of early-stage medically inoperable NSCLC.
State-of-the-art review of the evolving treatment landscape for small-cell lung cancer, published in Lancet, summarizing current standards and emerging targeted/immune approaches (ADCs, T-cell engagers, radioconjugates) likely to shape future management.
Systematic review and meta-analysis of phase 3 trials examining how patient sex and timing (neoadjuvant vs adjuvant) affect outcomes with curative-intent immune checkpoint inhibitors across solid tumors, published in JAMA Network Open. Findings could inform how oncologists interpret and sequence perioperative immunotherapy across tumor types by patient sex.
Biomarker analysis from a phase 1/1b trial of the B7H3-targeting ADC YL201, published in Clin Cancer Res, focused largely on NSCLC patients. Shows baseline neutrophil-to-lymphocyte ratio predicts response, PFS, and toxicity to this ADC, potentially informing patient selection and monitoring for this emerging agent.
Phase 1 trial with biomarker analysis in high-risk locally advanced HPV+/- head and neck squamous cell carcinoma, published in Clinical Cancer Research, combining the PI3K inhibitor buparlisib with chemoradiotherapy. Identifies TRAF3/CYLD loss-of-function mutations associated with response, suggesting a potential biomarker-driven strategy for PI3K pathway targeting in this setting.
Post-hoc long-term survival analysis of a multicentre stepped-wedge cluster-randomized trial in stage I-IV lung cancer, published in Lancet Oncol, evaluating whether patient-reported symptom monitoring improves overall and progression-free survival. Suggests routine PRO symptom tracking during treatment could meaningfully extend survival, supporting broader implementation in clinical workflows.
Retrospective real-world cohort study from a French early-access program, published in Lung Cancer, reporting long-term outcomes of first-line nivolumab plus ipilimumab in unresectable pleural mesothelioma. Confirms real-world effectiveness and safety consistent with trial data, supporting continued use as standard first-line therapy.
Narrative review in CA: A Cancer Journal for Clinicians outlining a proposed risk-adaptive, biomarker- and AI-driven paradigm for managing early-stage NSCLC, including perioperative immunotherapy and targeted therapy integration. Offers a conceptual framework rather than new data, useful for understanding evolving trends in early-stage lung cancer management.
Perspective/review in Clinical Cancer Research (elite journal) discussing MTAP loss as a targetable driver in NSCLC and the use of retrospective cohorts as historical controls for single-arm trials. Highlights an emerging biomarker-driven therapeutic avenue that oncologists should watch as early-phase trials mature.
Secondary/follow-up analysis of the phase III LAURA trial in unresectable stage III EGFR-mutant NSCLC, published in Clinical Cancer Research, reporting post-progression treatments and an early overall-survival interim analysis. Informs but does not change the established practice of adjuvant osimertinib after chemoradiotherapy, showing a trend toward OS benefit and delayed need for subsequent therapy.
Single-arm phase 2 trial of response-adapted, reduced-volume surgery following neoadjuvant immunochemotherapy in locally advanced HPV-negative head and neck squamous cell carcinoma, published in Clinical Cancer Research. Suggests a strategy to de-escalate surgery in strong responders while maintaining good outcomes, informing but not yet defining standard practice.
Post-hoc long-term safety analysis of the phase 3 FLAURA2 trial in EGFR-mutant advanced NSCLC, published in Lung Cancer. Characterizes how adverse-event patterns evolve across induction, maintenance, and osimertinib-only periods, informing toxicity management expectations for this now-standard combination regimen.
Phase Ib trial combining a PD-1 antibody with an EGFR antibody in recurrent/metastatic head and neck squamous cell carcinoma, published in Cancer Medicine. Shows promising response rates, especially in systemic-therapy-naïve patients, supporting further study of this checkpoint-inhibitor/EGFR combination.
Multi-omic translational study in NSCLC patients undergoing neoadjuvant therapy, published in J Immunother Cancer, identifying HIF1A+CSF3R+ neutrophils as drivers of a hypoxic, resistant niche linked to treatment non-response, with a proposed targeted combination validated in mouse models—informs biomarker-guided strategies to overcome neoadjuvant resistance.
Translational study in J Immunother Cancer using spatial proteomics to identify tumor-cell OX40L as a biomarker of response to first-line pembrolizumab in PD-L1-high NSCLC, validated across independent neoadjuvant cohorts. Suggests a potential marker to help personalize PD-1 blockade use.
Single-arm phase 2 trial of chemotherapy-free neoadjuvant camrelizumab plus apatinib in resectable HNSCC, published in Clinical Cancer Research. Shows modest pathological response rates linked to PD-L1 CPS and circulating tumor cell clearance, suggesting biomarker-guided selection for this chemo-free approach but not yet practice-changing.
Retrospective multicenter cohort study of synchronous oligometastatic NSCLC patients, published in Lung Cancer. Suggests multimodal therapy combining systemic treatment with local therapy (especially complete surgical treatment of all lesions) improves survival compared to systemic therapy alone, supporting aggressive local consolidation in this subgroup.
Single-arm phase II platform trial cohorts (National Lung Matrix Trial) in immune-checkpoint-resistant KRAS-mutant and wild-type advanced NSCLC, published in Clinical Cancer Research, testing ceralasertib plus durvalumab. Shows modest disease-control activity with limited objective responses, providing an early efficacy signal but not practice-changing.
Small, prematurely terminated single-center cohort from a randomized phase 2 trial of neoadjuvant intratumoral TLR7/8 agonist plus pembrolizumab or IL-2 in locally advanced oral cancer, published in Cancer Immunol Immunother; descriptive only due to tiny sample size, offering early feasibility/safety signal rather than definitive efficacy data.
Retrospective multicenter cohort study validating an AI algorithm for scoring pathologic response after neoadjuvant chemoimmunotherapy in NSCLC, published in Lung Cancer. Suggests AI could standardize pathologic response assessment across institutions, but does not itself guide a specific treatment decision.
Descriptive analysis of FDA (neo)adjuvant drug approvals for solid tumors (2010-2023), published in JNCI, spanning melanoma, breast, and lung cancer trials. Highlights inconsistencies in trial design, endpoint reporting, and quality-of-life data that inform how oncologists interpret the evidence behind approved (neo)adjuvant regimens.
Retrospective cohort study (with propensity matching) of recurrent/metastatic nasopharyngeal carcinoma patients on checkpoint inhibitors, published in European Journal of Cancer. Suggests adding local therapy to immunotherapy may improve progression-free survival, supporting consideration of consolidative local treatment alongside ICI in this setting.
Single-arm phase 2 trial in locally advanced head and neck squamous cell carcinoma, published in Journal for ImmunoTherapy of Cancer. Tests neoadjuvant chemoimmunotherapy plus afatinib before surgery, showing encouraging pathologic response rates that could inform future neoadjuvant regimen design pending randomized confirmation.
Commentary/perspective in Clin Cancer Res discussing recent genomic characterization of KRAS Q61-mutant NSCLC and allele-specific heterogeneity. Highlights implications for future patient stratification in RAS-directed therapy development but does not itself report new clinical trial data.
Retrospective real-world cohort comparing neoadjuvant immunochemotherapy versus chemotherapy alone in limited-stage small-cell lung cancer, published in Lung Cancer. Suggests improved pathologic response and disease-free survival with the addition of immunotherapy before surgery, informing but not yet establishing a new neoadjuvant standard.
Retrospective molecular concordance study in Lung Cancer (Q2) examining KRAS mutation stability/discordance across paired NGS samples in lung adenocarcinoma, including its use to distinguish multiple primary tumors from metastases. Informs when serial KRAS retesting may be warranted, particularly after neoadjuvant therapy or for staging clarification, rather than direct treatment selection.
Population-based Dutch registry study in Lung Cancer examining how chemotherapy-free interval influences outcomes of second-line topotecan versus platinum rechallenge in extensive-stage SCLC. Suggests platinum rechallenge may be preferable to topotecan for relapses beyond 90 days, informing second-line treatment choice.